At the 2nd general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s (IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding blood cancer.
The alliance, which brings together 51 partners and key stakeholders from eleven European countries, uses its big data platform to better understand blood cancer and contribute to improving targeted therapies.
Michel Van Speybroeck, director of data sciences, Janssen, said: “Public and private partners are bringing together their best people, data and knowledge to solve key questions on haematological cancers.
“These challenges can only be met by applying the most advanced technology and it’s wonderful to see from the front-line how this is being shaped by the Harmony Alliance.”
The alliance aims to offer an ethical and legal framework on the use of medical data, using its new platform for analysis and defining “standard sets of outcomes”.
